Neurotherapeutics (2015) 12:911 DOI 10.1007/s13311-015-0389-z
ERRATUM
Erratum to: Parsing Physiological Functions of Erythropoietin One Domain at a Time Lawrence Steinman 1
Published online: 10 September 2015 # The American Society for Experimental NeuroTherapeutics, Inc. 2015
Erratum to: Neurotherapeutics DOI 10.1007/s13311-015-0384-4 Appropriate credit for discovery of a peptide component of erythropoietin that elicits neuroprotection without stimulating erythropoiesis rightfully belongs to Anthony Cerami and colleagues. They have published a series of papers over the past decade on the identification of the peptide (1), mapping its receptor (2), and even translating the work into clinical trials (3,4,5). It is important that their work is recognized in Neurotherapeutics.
2.
3.
4.
5. 1.
Brines, M., Patel, N.S., Villa, P., Brines, C., Mennini, T., De Paola, M., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105(31), 10925–10930.
The online version of the original article can be found at http://dx.doi.org/ 10.1007/s13311-015-0384-4. * Lawrence Steinman
[email protected] 1
Neurology and Neuroscience, Stanford University School of Medicine, Stanford, CA 94305, USA
Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., et al. (2004). Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 101(41), 14907– 14912. Niesters, M., Swartjes, M., Heij, L., Brines, M., Cerami, A., Dunne, A., et al. (2013). The erythropoietin-analogue ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Exp Opin Orphan Drugs 1, 77–87. van Velzen, M., Heij, L., Niesters, M., Cerami, A., Dunne, A., Dahan, A., et al. (2014). ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs 23(4), 541–550. Collino, M., et al., Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a nonerythropoietic small peptide engineered from erythropoietin, Pharmacology & Therapeutics, in press (2015). http://dx.doi.org/10.1016/j. pharmthera.2015.02.005
